Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a strong-buy rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.

Several other equities analysts also recently commented on the stock. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a hold rating to a buy rating in a report on Friday, July 19th. Cantor Fitzgerald downgraded shares of Arrowhead Pharmaceuticals from an overweight rating to a neutral rating and set a $24.00 price target on the stock. in a report on Thursday, June 27th. TheStreet upgraded shares of Arrowhead Pharmaceuticals from a d rating to a c+ rating in a report on Thursday, May 30th. B. Riley upped their price target on shares of Arrowhead Pharmaceuticals from $26.00 to $32.00 and gave the company a buy rating in a report on Tuesday, May 28th. Finally, Piper Jaffray Companies upped their price target on shares of Arrowhead Pharmaceuticals from $25.00 to $33.00 and gave the company an overweight rating in a report on Tuesday, April 16th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $27.50.

NASDAQ:ARWR traded down $0.41 during mid-day trading on Thursday, hitting $29.12. 729,612 shares of the stock traded hands, compared to its average volume of 982,731. The stock has a market cap of $2.76 billion, a PE ratio of -44.80 and a beta of 1.59. Arrowhead Pharmaceuticals has a 52 week low of $10.41 and a 52 week high of $30.73. The stock has a 50 day moving average price of $27.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.22 by $0.02. The company had revenue of $48.15 million for the quarter, compared to the consensus estimate of $45.78 million. Arrowhead Pharmaceuticals had a net margin of 10.09% and a return on equity of 6.72%. As a group, research analysts expect that Arrowhead Pharmaceuticals will post 0.71 EPS for the current fiscal year.

In other Arrowhead Pharmaceuticals news, General Counsel Patrick O’brien sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $24.88, for a total value of $746,400.00. Following the completion of the sale, the general counsel now directly owns 203,000 shares of the company’s stock, valued at approximately $5,050,640. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Kenneth Allen Myszkowski sold 27,071 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $22.00, for a total transaction of $595,562.00. Following the completion of the sale, the chief financial officer now directly owns 278,536 shares of the company’s stock, valued at $6,127,792. The disclosure for this sale can be found here. Over the last three months, insiders sold 74,827 shares of company stock valued at $1,832,205. 4.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in ARWR. Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 8.1% in the 4th quarter. Geode Capital Management LLC now owns 996,458 shares of the biotechnology company’s stock worth $12,375,000 after purchasing an additional 74,295 shares during the period. New York State Common Retirement Fund lifted its position in shares of Arrowhead Pharmaceuticals by 2.8% in the 1st quarter. New York State Common Retirement Fund now owns 371,657 shares of the biotechnology company’s stock worth $6,820,000 after purchasing an additional 10,035 shares during the period. Bank of America Corp DE lifted its position in shares of Arrowhead Pharmaceuticals by 812.8% in the 4th quarter. Bank of America Corp DE now owns 333,938 shares of the biotechnology company’s stock worth $4,148,000 after purchasing an additional 380,784 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Arrowhead Pharmaceuticals by 84.8% in the 1st quarter. JPMorgan Chase & Co. now owns 303,245 shares of the biotechnology company’s stock worth $5,564,000 after purchasing an additional 139,154 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Arrowhead Pharmaceuticals by 482.3% in the 2nd quarter. First Trust Advisors LP now owns 173,413 shares of the biotechnology company’s stock worth $4,595,000 after purchasing an additional 143,632 shares during the period. 62.46% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Featured Story: QQQ ETF

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.